Aortech Share Price (AOR)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Aortech International Plc	LSE:AOR	London	Ordinary Share	GB0033360586	ORD 5P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.00%	52.50	0.00	01:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
50.00		55.00	52.50	52.50	52.50

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	0.54	-0.04	-0.79		8.0

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
-	O	0	0.00	GBX

Related Shares
Smith & Nephew (SN.), Nmc Health (NMC), Physiomics (PYC), Salvarx (SALV)

Aortech (AOR) Latest News

Aortech News

Date	Time	Source	Headline
17/7/2019	10:59	ALNC	AorTech Shares Fall After Annual Loss Deepens Amid Doubling Costs
17/7/2019	07:42	ALNCF	Alliance News Flash Headline
17/7/2019	07:00	UKREG	AorTech International PLC Final Results
08/7/2019	11:05	UKREG	AorTech International PLC Second Price Monitoring Extn
08/7/2019	11:00	UKREG	AorTech International PLC Price Monitoring Extension
19/6/2019	07:01	UKREG	AorTech International PLC Change of Adviser
19/6/2019	07:00	UKREG	AorTech International PLC Directors' Disclosures
17/6/2019	10:47	UKREG	AorTech International PLC Directors' Disclosures
14/5/2019	15:37	ALNC	AorTech Sees Double-Digit Annual Revenue Growth, Confident On Outlook
14/5/2019	07:00	UKREG	AorTech International PLC Trading Update

More Aortech News

Aortech Takeover Rumours

Aortech (AOR) Share Charts

1 Year Aortech Chart

1 Month Aortech Chart

Intraday Aortech Chart

Aortech (AOR) Discussions and Chat

Aortech Forums and Chat

Date	Time	Title	Posts
17/7/2019	21:50	Aortech International – New Projects, New Partners, New Targets	2,643
16/6/2018	00:12	Aortech - Interesting Biomaterials Business. Market Cap All Cash	4,728
03/7/2015	17:20	Upwards	1
19/1/2007	16:00	Aortech with Charts & News	6
07/4/2006	17:46	Wakey Wakey! - Aortec in bid talks......	70

Add a New Thread

Aortech (AOR) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-07-17 16:15:00	51.00	95,000	48,450.00	O
2019-07-17 13:23:40	52.00	50,000	26,000.00	O
2019-07-17 12:33:56	53.15	918	487.92	O
2019-07-17 11:54:50	51.00	5,000	2,550.00	O
2019-07-17 11:33:31	51.00	50,000	25,500.00	O

View all Aortech trades in real-time

Aortech (AOR) Top Chat Posts

Date	Subject
17/7/2019 09:20	Aortech Daily Update: Aortech International Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AOR. The last closing price for Aortech was 52.50p. Aortech International Plc has a 4 week average price of 51.50p and a 12 week average price of 51.50p. The 1 year high share price is 99p while the 1 year low share price is currently 41.50p. There are currently 14,686,608 shares in issue and the average daily traded volume is 116,308 shares. The market capitalisation of Aortech International Plc is £7,710,469.20. Read Full Thread Reply
17/7/2019 08:19	harrogate: Results out but nothing new. As we know it is all about the reality or not of the IP for the development programmes they are undertaking. Milestones to be hit in next year. No reason to expect share price to move up on this so we live in hope ( maybe not expectation ) ! Read Full Thread Follow Reply
10/7/2019 14:57	bones: A phenomenon I have noted in several small shares lately is for punters (no other word applies) to buy a chunk only to sell the lot, sometimes the same day and sometimes a day or two later, almost always at a loss. The raison d’etre seems to be that the purchase either creates or follows momentum following which a quick profit can be grabbed for a few points. Yet, usually, that never happens. I find it hard to believe that the person who bought 30,000 AOR two days ago at 60p would be the same as the one who has dumped the same amount today at 58.2p. The spread has been a killer lately due to illiquidity. I don’t rule it out though given the desperate gamblers that seem to be present in our markets. Investors are the silent majority I guess. Anyone want to own up? :) As CHF says, the net effect of the two trades is a share price up by 5p, so the sale today was easily absorbed. It’s not really a surprise given how oversold the share was on the RSI reading (at under 10 which is stupidly low). Read Full Thread Follow Reply
12/6/2019 17:33	bones: Well, we know Miton decreased to around 6% from 9% but they sold a lot of stock across the board when they were hit for redemptions after AIM crashed late last year (a mini version of Woodford you might say!). WB is well up around 16% but they are just nominees for PI’s on the whole. Problem for AOR is they are too small to attract proper institutions currently so the share price is subject to the mood swings of PI’s. Fortunately, I think most of those invested are sticky and sane types :) All the signs are that the second half of 2019 should see more activity in AOR as prototyping, manufacturing and testing takes place ahead of the hoped for CE Marks on the grafts and patches. Anything to do with progress on the heart valve is all “bunce” as far as I am concerned. The pot of gold lies somewhere over yonder! Read Full Thread Follow Reply
05/6/2019 16:57	coolhandfluke: Hi Bones,My take on AOR at the moment is that people are trading this share. Notwithstanding news that would move the share price in a positive way , hopefully, traders are loading up between 50 and 60p moving the price up, then selling between 70and 80p bringing the price back down. So until we move to the next development level, expect to move between 50 and 80p.CheersCHF Read Full Thread Follow Reply
17/5/2019 09:45	coolhandfluke: Can't believe all these sells yesterday and today are not having too much of an adverse affect on the share price? Must be at the right level following recent positive update. Read Full Thread Follow Reply
14/5/2019 13:01	harrogate: A decent update - key is cash balance and that seems ok as we don't want to be doing a raise at these levels if we can help it. It is now clear that AOR is a bet on the HV and other new developments - despite some of the warm words at the time of the fundraising last year there are no imminent new licensing deals for the core materials and I suspect that the increase in licence fee income is more about exchange rates than growth. But that is ok for me as I never believed they would come through anyway - as has been said above it is the timing, name and deal size on the inevitable licence / partnership deal with a large medical device company that we now await and maybe a share price that sneaks up will tell us it is coming! Read Full Thread Follow Reply
03/4/2019 08:42	bones: The term “femtech”; seems to attract stupid money from VC’s. Best AOR includes it in any RNS about the polymer implants? Should do wonders for the share price.... Read Full Thread Follow Reply
09/1/2019 20:19	bones: To pass the time, I've been doing a bit of digging in Companies House on a few companies of interest to me (not just AOR). I found an intriguing development on AOR, albeit purely administrative: As of last week, the Company Secretary role (which is a legally important appointed officer role that requires disclosure at Companies House) changed at Aortech International plc and its subsidiaries. The new Company Secretary is now a lady called Kathryn Full. She has one other Company Secretary role disclosed at Companies House and that is and remains Co Sec (since 2010) for Vascular Flow Technologies Ltd ("VFT"), the company that AOR has appointed to do all of its work on the heart valve development following the fund raising in June 18. The previous Co Secretary was based at the AOR Surrey HQ which makes me speculate that they might close those offices (?) seeing as they seem to have no geographical purpose now that all the action is in Scotland (and the USA where John Ely, the non-exec director and heart valve expert for AOR resides, as does Biomerics LLC, AOR's contract polymer manufacturer). VFT is essentially an R&D company these days. It makes very little turnover yet, over the years, has burned through £20M if I read the accounts correctly, some of it financed from offshore investors. There was a $10m financing round in 2016 which cleared out some previous investor loans. Clearly though, the cutting edge work they are doing on blood flow computer simulation (from which AOR hope to benefit) has massive potential. VFT's private shareholder structure seems convoluted, not surprising I guess. The investors there must be impressed as they keep topping up to finance the progress. Anyway, my interest has been piqued by this change of Co Sec at AOR. It seems to be somehow significant that they have taken on the person from their R&D partner, VFT which is independent in all other respects, with its own customers. Perhaps the thinking was simply the need to have someone based in Scotland and that this person came highly recommended. Perhaps it was a requirement of Scottish Enterprise to have Scottish officers and offices? Maybe there is more to the relationship going forward between AOR and VFT? I am merely thinking and speculating aloud but think it is of interest, especially as I have a decent-sized personal interest in the quoted shares of AOR and information is not readily made available as the share price shoots all over the shop! Read Full Thread Follow Reply
15/6/2018 23:49	bones: INTRODUCTION AorTech International plc holds patents, know-how and trade secrets relating to a family of bio-compatible materials. A large range of polymers has been developed within the Elast-Eon(TM) family with different mechanical properties, such as hardness and elasticity. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals. COMPANY WEBSITE: hTTps://www.aortech.net/ BACKGROUND After several years of under-performance, containing more than its fair share of failed strategies and legal disputes with customers, partners and an ex-CEO (settled amicably in December 2017 for an undisclosed sum paid to AOR), Aortech is finally clear for take off! A new strategy for the company, incorporating the benefits of its long held, valuable IP assets, has finally been revealed (in May 2018); new investors have been rounded up to join the patient ones and top personnel have been recruited. Fresh money is in the bank ready to exploit the new frontiers in cardiovascular medical devices and cosmetic implants. SOME STATS Market capitalisation (June 18) = £6 MILLION Cash in bank (June 18) = £3 MILLION Invested in current proven technology to date = £60 MILLION (including £30 MILLION in heart valve R&D) Partnered with Vascular Flow Technologies for their Spiral Laminar Flow (TM) blood flow technology - see htTps://vascular-flow.com/our-technology/ . VFT appear (from reading their accounts) to have invested £20M into this over several years, so AorTech is leveraging this R&D for a fraction of the cost. STRATEGY Aortech is now seeking to maximise value from its IP portfolio by developing certain products while maintaining what the directors believe to be a low cost/risk business model. As part of this strategy, the company is entering into a development and manufacturing agreement with RUA Medical - click here hTTp://www.ruamedical.com - a medical textiles manufacturer, and a development contract with Vascular Flow Technologies - click here hTTp://vascular-flow.com - a medical device development company. If successfully developed and approved by the relevant regulatory authorities, the company proposes to employ a lean sales and marketing strategy for its products, a distribution model to provide access to hospital markets and OEM sales of devices to other medical device companies. Initial product pipeline is to be: 1. Cardiovascular and soft tissue patches 2. Large bore grafts 3. Synthetic heart valve Three new non-executive directors have been recruited, two of whom are from the highest echelons of the cardiovascular world! John Ely (NED - Heart Valve Expert) Geoffrey Berg (NED - Cardiovascular Expert) See this RNS and Offer document for all the details about these products and new directors: hTTps://uk.advfn.com/stock-market/london/aortech-AOR/share-news/AorTech-International-PLC-Conditional-Placing-and/77473499 hTTps://www.aortech.net/wp-content/uploads/2018/05/249297-Project-Amplify-Circular-WEB.pdf AORTECH IN THE PRESS Essential introduction here (Scottish Herald 7th July 2018): hTTp://www.heraldscotland.com/business_hq/16339604.heart-valve-pioneer-aortech-international-returns-to-its-scottish-roots/ Video Interview with John McKenna, AOR director (CTSNet.org 6th December 2018): hTTp://www.ctsnet.org/article/pioneers-cardiac-surgery-john-mckenna Interactive Investor website - “Five AIM growth shares for your 2019 ISA” (ii.co.uk 1st March 2019) hTTps://www.ii.co.uk/analysis-commentary/five-aim-growth-shares-your-2019-isa-ii507804 INTRO VIDEO ABOUT AORTECH'S HEART VALVE Aortech acquired the original IP from CSIRO in the early 2000's - click this link hTTps://csiropedia.csiro.au/elast-eon-biocompatible-polyurethane/. Now AOR is finally funded to complete stage one of the quest to commercialise the holy grail that is the synthetic heart valve. This video is the basic introduction to the technology (note the reference to Aortech in it). !YOUTUBEVIDEO:qfzXvuh2xxc: THE DISRUPTIVENESS OF POLYMER HEART VALVES To gain an idea of how AOR is standing on the cusp of a disruptive change to a huge industry, please refer to the following posts by Landy90 who has some knowledge of the cardiovascular industry: 2383, 2385, 2390, 2394, 2398, 2399 As always, BB posts are opinion only, so always do your own research! DIRECTOR EMI OPTIONS VEST WHEN SHARE PRICE REACHES 300p On page 46 of the Open Offer document (May 2018), the following is found: As regards options to be granted to any Director, such options will vest as to 20 per cent. after the expiry of 3 years from the date of grant, 30 per cent. on the receipt by the Company of a CE Mark for any of its products and 50 per cent. on the closing middle market quotation of the Ordinary Shares, as derived from AIM Appendix to the Daily Official List of the London Stock Exchange, being at least £3.00, being 10 times the Issue Price, for 10 consecutive days on which trading takes place on AIM. BROKER NOTE 400p INITIAL TARGET PRICE Stockdale Securities' report can be accessed via Research Tree but you have to sign up, albeit there is a free 7 day trial (with your payment details): hTTps://www.research-tree.com/companies/uk/medical-equipment-services/aortech-international/research/stockdale-securities/new-projects-to-drive-shareholder-value/ae347ba2-3cc8-47d7-8789-96d2eb7972f5 Excerpt: BROKER NOTE UPDATE 21/2/19 RETAINING 400p TARGET PRICE Stockdale Securities issued a new comment in Feb19 about an industry development on polymeric heart valves that have a direct read through to Aortech’s business strategy. The following is their executive summary: "We view positively the news earlier this week that the FDA has granted Foldax Inc. investigative device exemption (IDE) approval for an Early Feasibility Study of its Tria surgical aortic heart valve to treat aortic valve disease. This is because it sets the path to commerciality for AorTech with its polymeric heart valve, which uses its patented Elast-Eon polymer. With milestones set to be achieved in both the heart valve and textiles projects in 2019 and 2020, we expect to see a significant increase in news flow. We retain our 400p TP and Buy rating." TRADING UPDATE 14th MAY 2019 Excerpts: “Our strategy of transitioning AorTech into a medical device manufacturer is progressing well with much having been achieved over the last year.” “The business model of working with partners means that progress has been made on a highly cost effective basis.” “We remain confident of delivering further progress in the current year.” “The development focus has been on heart valve design and the synthesising of materials for vascular prothesis. This phase is now nearing completion.” “Prototyping, manufacturing and testing will become the Company's principal focus over the coming year.” “Much technical planning has been undertaken as part of the design for manufacture process to identify the most up to date equipment available to automate and ensure repeatability of the manufacturing processes.” “Our team has identified an opportunity to significantly improve the way the heart valves are manufactured and, if successful, should allow optimised polymer heart valve designs to be manufactured with reduced costs.” RNS UPDATE 24th JANUARY 2019 Excerpts: Heart Valve Project ”AorTech's novel "Leaflet Builder" software utilising Computational Fluid Dynamics has been completed and has successfully replicated, not just the leaflet design described in AorTech's patents, but has also accommodated any correction factors required to simulate the last design iteration of the AorTech valve.” ”Work has now started on planning the future manufacturing process with the objective of designing a process, and specifying the machinery required, to manufacture valves of a consistently high quality and by a process that is verifiable from a regulatory perspective that minimises manufacturing costs and will be scalable to allow commercial volumes to be produced.” Textile Projects ”Our partners at RUA Medical have successfully manufactured yarn which has been specifically designed for both our patch and grafts products. The yarn has now been converted into textile and the initial results have been very encouraging and more than meet our initial expectations.” ”AorTech believes that the process of designing the yarn and textile for specific use, rather than designing a graft around existing yarn technology, is a major improvement in graft development and, as such, the new products will represent a major improvement over technology currently available in the market.” Patent Issue ”AorTech is pleased to announce that the US Patent and Trademark Office has issued notice that Patent Number 10,195,834 entitled "BONDING PROCESS" will be issued on 5 February 2019. The invention relates to a process for bonding a silicone or silicone-based material to a polyurethane and use of the bonded silicone-polyurethane in the manufacture of biomaterials, devices, articles or implants, in particular long term implantable medical devices.” RNS UPDATE 22nd NOVEMBER 2018 Interim Results ”We have also made good progress in confirming both market need and interest in our products. At a recent European Cardiothoracic meeting of some 3,000 surgeons and industry players, we engaged with a number of parties, including key surgeons, large industry players and product distributors, and explained which products AorTech would be bringing to the market. Feedback was very positive and the market need was confirmed for both the valve and polymer coated textile products.” https://uk.advfn.com/stock-market/london/aortech-AOR/share-news/AorTech-International-PLC-Interim-Results/78740355 RNS UPDATE 23rd AUGUST 2018 AGM Statement Excerpts: "On the heart valve project, technology transfer has been completed with Vascular Flow Technologies Limited ("VFT") which is now actively engaged with John Ely.....on design optimisation." "The textile-based products are also on track with RUA Medical, in association with our polymer manufacturing partner, Biomerics Inc., and have now identified the optimal version of Elast-Eon(TM) to provide the patches and grafts with the required properties." "The polymer licensing business is performing to plan and continues to meet the Board's expectations." "We are also delighted to have been informed that the US Patent and Trademark Office will issue US Patent Number 10,059,807 on a new AorTech patent entitled GELS further building on our family of biostable materials." Overall, we are delighted with how the business is progressing and look forward to the future with confidence." RNS UPDATE 4th JULY 2018 New Patent Issued Excerpt: AorTech is pleased to announce that the Brazilian Patent Office has recently granted Patent Number PI 0711694-2 entitled Biostable Gels. The invention relates to biostable gels, the processes for their preparation and their use in the manufacture and repair of biomaterials and medical devices or implants, in particular soft tissue implants such as breast implants. Bill Brown, Chairman of AorTech said: "The issue of this patent further expands AorTech's patent portfolio, particularly in the area of breast implants. Brazil is one of the largest markets for breast enhancement outside of the USA and is therefore an important patent territory. The portfolio of IP relating to Breast Implants is not currently licensed by AorTech." RNS UPDATE 28th JUNE 2018 Development and Supply Agreement with RUA Medical Excerpt: AorTech has appointed RUA Medical as its development and manufacturing partner to bring the immediate opportunities from this platform technology to market. Bill Brown, Chairman of AorTech said: "In anticipation of entering into this agreement, the AorTech and RUA Medical teams have gone through a detailed project planning process. This process has confirmed to AorTech that RUA Medical is the ideal partner for this project and that its unique combination of R&D, project management, regulatory and manufacturing expertise should help us deliver the soft tissue pericardial patches and large bore grafts to market in a highly efficient manner." Caroline Stretton, Chief Executive Officer of RUA Medical said: "The team at RUA Medical is delighted to be partnering with AorTech on the development and supply of their transformational devices. Superior safety and performance, in conjunction with secure supply, will afford spectacular improvements to the quality of life of end users. RUA Medical also recognises the exciting future prospect of exploiting further medical device opportunities within AorTech's novel platform technology." RNS UPDATE 26th JUNE 2018 New Patent Issued Excerpt: AorTech is pleased to announce that the US Patent Office has recently granted Patent Number 9,994,668 entitled "BIOSTABLE POLYURETHANES". The invention relates to polyurethanes and processes for their preparation. The polyurethanes are biostable, creep resistant, acid resistant and abrasion resistant which makes them useful in the manufacture of biomaterials and medical devices, articles or implants, in particular, long term implantable medical devices in the fields of cardiology, orthopaedics, plastic surgery and gastroenterology. Bill Brown, Chairman of AorTech said: "We are delighted that this US Patent has been issued extending further AorTech's world class portfolio of biostable polymers for medical device use." RNS UPDATE 19th JUNE 2018 Development Agreement signed with Vascular Flow Technologies Limited ("VFT") Excerpt: Bill Brown, Chairman of AorTech, said: "In partnering with the team at VFT, AorTech now has access to Europe's leading experts in the combined field of medical imaging, guided Finite Element Analysis and Computational Fluid Dynamics. Combining the design history with this ground breaking imaging analysis should much improve the quality of the product design, reliability and performance." Craig Dunlop, General Manager and Director of VFT, said: "The team at VFT has been very impressed with the quantity and quality of data that AorTech has been able to demonstrate to us. We are very excited to be a key partner in the development of the next generation of prosthetic heart valves which should represent not only a step change in performance, but dramatically reduce the cost to manufacture these life enhancing devices." SIGNIFICANT SHAREHOLDERS ( > 3% ) AS AT 16th APRIL 2019 16.38% Walker Crips Stockbrokers (2,406,092) 5.87% Miton Asset Management (862,071) 5.24% Clive Titcomb and family interests (770,000) 4.60% Hargreaves Lansdown Asset Management (675,753) 4.37% Mr Gordon Wright (641,645) 3.99% Share Centre Investment Management (586,229) 3.70% Mr JD Abell (543,399) 3.46% Interactive Investor (507,890) 3.45% Mr Bill Brown (506,649) Read Full Thread Follow Reply
30/1/2018 10:46	the stigologist: These are another set of notes I wrote after previous RNSes. Just FYI FWIW for any newbies getting up to speed. So the basics on this are that they developed this Elast-eon technology about 17 years ago. Failed to become a device manufacturer themselves. Licensed the materials tech unsuccessfully initially and on bad terms to much bigger players. Got into loads of litigation to try to protect their Intellectual Property etc. Finally seem to have drawn a line under previous litigation and found a licensing partner Biomerics who is delivering. Reckon that having learnt from previous experiences they can licence their tech successfully for some other devices e.g. Breast implants and Heart Valves. Their current valuation is totally out of sync with what even Private Start-ups are valued at (e.g. Edwards buying Harpoon a couple of weeks ago for $100-250m) which don't have the track record of successful clinical use or FDA approvals. AOR AorTech Share Price : 50p Market Cap : £2.8m AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals. Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available. Valuation comparitors :- Major licensee is Biomerics. Private Company. Recently spent $38m on a HQ building alone. hTtp://biomerics.com/elast-eon-bringing-quality-value-medical-device-project/ Edwards Lifesciences bought Harpoon Medical for $100-250m (December 6th 2017) hxxp://www.edwards.com/ns20171206 "The HARPOON system is designed to facilitate echo-guided repair of mitral valve regurgitation, by stabilizing the prolapsed mitral valve leaflet to restore proper coaptation and valve function" Xeltis achieved largest private equity funding round for a medical device in Europe of $52m in 2017 (November 15th 2017) hTtp://www.xeltis.com/news/xeltis-closes-e45-million-series-c-financing/ AorTech comments :- General licenses :- "Significant funding has been achieved by AorTech licencees in developing and commercialising their products with AorTech's Elast-Eon™ seen as critical to their success. In one instance, funds in excess of $100 million have been raised to achieve successful commercialisation." On their Heart Valve Project :- "We have previously announced a potential transaction with a new business established to commercialise the AorTech heart valve technology. Fund raising for the new project is continuing but is not yet finalised and any license will be dependent upon the new business being fully funded. The package of data and information that AorTech is able to deliver to the project is substantial. This ranges from specific manufacturing know how and trade secrets for the precise polymer best suited to a heart valve, detailed design files for a polymer valve with a stress/strain profile substantially less than the material mechanical properties, together with a fully documented manufacturing process that allows a clinical quality valve to be made on a repeatable basis. All of these processes have been developed over a number of years of trial and error and experimentation at considerable investment by AorTech." Read Full Thread Follow Reply

Aortech share price data is direct from the London Stock Exchange

Your Recent History

LSE

AOR

Aortech

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190718 07:50:54